Chronic Kidney Disease in Kidney Cancer Patients Anthony Chang, MD University of Chicago Medical...

Chronic Kidney Disease in Kidney Cancer Patients

Anthony Chang, MDUniversity of Chicago Medical Center

Outline

• Non-Neoplastic Kidney Diseases in Kidney Cancer

– Harmful – Common– Underappreciated

• Review common medical renal diseases associated with renal cancer

Chronic Kidney Disease (CKD)

• Previously known as “chronic renal failure”

• Defined as GFR <60 ml/min per 1.73 m2

• May progress to end-stage renal disease

• Involves 25% of renal cell carcinoma (RCC) patients prior to nephrectomy

• Diabetes and hypertension are independent risk factors for RCC

Chronic Kidney Disease (CKD)

• ↑ risk of CKD after radical compared with

partial nephrectomy

• ↑ risk of cardiovascular and non-

cardiovascular death

American Urological Association

• 2009 - T1 tumors (<7 cm) should be

treated with partial nephrectomy

• Emerging data that T2 tumors should also

be treated with nephron sparing surgery

“Despite mounting evidence that PN is an effective and preferable approach to the T1 renal mass, it remains markedly underutilized in the USA and abroad. The overzealous use of radical nephrectomy for T1 tumors must now be considered detrimental to the long term health of the kidney tumor patient.”

2004 US Renal System Data

• Expected life span on dialysis: 20 – 24 years: 14.6 years 60 – 64 years: 4.3 years 70 – 74 years: 3.1 years 80 – 84 years: 2.2 years

• RCC 5 year survival rates Stage 1 = >90% Stage 2 = 75-90% Stage 3 = 59-70% Stage 4 = <10% (median: 16-20 mos)

“As I spoke, the family seemed to relax visibly, and began to break into smiles. “Oh, that’s wonderful news, wonderful news!” I smiled too, automatically, although I did not think my news—a biopsy finding of advanced glomerulosclerosis, irreversible kidney failure—had been so wonderful. It was true that this particular kidney biopsy had been done because of heavy proteinuria and newly diagnosed kidney failure in a man with a lung nodule; the working diagnosis had been a paraneoplastic membranous nephropathy, and the specter of lung cancer had been hanging over the scene for the last few days. My news made the possibility of cancer recede. The nodule eventually was found to be benign, and we were left to deal with the aftermath of the not-cancer diagnosis, the good news that wasn’t.

If the one-year mortality for new end-stage kidney failure exceeds that for most new cancer diagnoses, why is it that this family, like many others, dreaded the latter more than the former?”

“I became very close with the patient who reacted with such relief to the diagnosis of advanced kidney disease rather than cancer. I saw him progress, quickly and inexorably, to dialysis-requiring kidney failure. I watched him suffer with infections, fatigue, confusion, and cramps. He lost his appetite, and became weak and bedbound. He died less than a year after I met him. To the end, I don’t think that he or his family ever understood that the news I had brought was bad, or that kidney failure itself had been the final blow to his fragile health. Perhaps it was for the best that they did not really understand.

Then again, that’s what oncologists used to say, in whispers, outside the rooms of patients who were pretending not to listen.”

Dena E. Rifkin, MD, MSLa Jolla, California

Non-Neoplastic Renal Diseases & Kidney Cancer

Non-Neoplastic Kidney Disease & Cancer

• 24 cases (9.8%)– 19 Diabetic nephropathy– 3 Thrombotic microangiopathy– 1 Focal segmental glomerulosclerosis– 1 Sickle cell nephropathy

• 21 (88%) – not originally diagnosed

• Of 147 pathology residency programs, 98 responded – only 35 (36%) require renal pathology rotation

Non-Neoplastic Kidney Disease & Cancer

• Cedars Sinai Medical Center – LA (2010 USCAP online abstract)– 311 nephrectomies– 66% nephrosclerosis (41% or 24% of total

were mild)– 7.4% - Diabetic nephropathy– 4.8% - Focal segmental glomerulosclerosis– 3% - Miscellaneous (amyloid, GN,

atheroemboli, etc.)

Non-Neoplastic Kidney Disease & Cancer

• Weill Cornell Medical College (2011 USCAP abstract)– 216 nephrectomy cases– 47 (21.7%) new pathologic diagnoses

• 21 – diabetic nephropathy• 11 – hypertensive nephropathy• 6 – focal segmental glomerulosclerosis• 2 – collapsing glomerulopathy• Arteriolar sclerosis predictive of renal function

decline

Non-Neoplastic Kidney Disease & Cancer

• 110 tumor nephrectomy (60 prospective)• 38% - Normal• 24% - Diabetic nephropathy• 28% - Severe scarring• Misc (IgA, collapsing GP, amyloid, etc)

Incidence in TN specimens

• Arterionephrosclerosis >20%

• Diabetic nephropathy 10-20%

• Focal segmental GS 2-9%

• Thrombotic microangiopathy 3-5%

• AA amyloidosis 3%

• Atheroembolic disease 2%

• IgA nephropathy 2%

• Membranous nephropathy <1%

Grossing Nephrectomy Specimens

• Should you obtain a fresh tissue sample

for IF and EM?

• Order the PAS/Jones silver stain on the

non-neoplastic kidney tissue block

Algorithm

• Identification of glomerular abnormalities

– First, light microscopy!

• Glomeruli

• Tubules

• Interstitium

• Vessels

Glomeruli

Normal Mesangial sclerosis Mesangial hypercellularity

Crescent / fibrinoid necrosis Segmental Sclerosis Endocapillary hypercellularity

Algorithm

• If glomerular abnormalities present,– Consider Congo red – Immunofluorescence microscopy (IgG, IgA,

IgM, kappa/lambda light chains, albumin) on paraffin tissue sections

• Decreased sensitivity compared with frozen tissue

– Immunohistochemistry– Electron microscopy from paraffin block

• Preservation/processing artifact

Tubules / Interstitium

Normal Interstitial fibrosis / tubular atrophy

Interstitial inflammation Acute tubular injury

Vessels

Intimal fibrosis Hyalinosis Thrombus

Atheroembolus Vasculitis

Diabetic Nephropathy

• Diabetes is a risk factor for RCC

• 8% of American adults c diabetes

• 10-20% of RCC patients have diabetes

• DN in up to 8-20% of TN specimens

• Diabetic nodular glomerulosclerosis predicts progression of CKD

• Treatment: Strict blood glucose control

Diffuse Mesangial Sclerosis

Nodular Mesangial Sclerosis

Capsular Drop

Arteriolar Hyalinosis

Nodular Glomerulosclerosis

• Differential diagnosis– Diabetic nephropathy– Amyloidosis– Monoclonal Immunoglobulin Deposition Disease

• Light chain deposition disease

• Light and heavy chain deposition disease

– Fibrillary GN– Immunotactoid glomerulopathy– Idiopathic nodular glomerulosclerosis

• Associated with hypertension and smoking

Amyloidosis

• ~3% of RCC with AA amyloidosis

• Rare cases of AL amyloid and other

amyloid forming proteins

• Treatment: removal of neoplasm

• Proteinuria may indicate recurrent or

metastatic disease

Amyloidosis

Arterionephrosclerosis

• AKA Hypertensive nephropathy / nephrosclerosis

• Hypertension in 25-60% of RCC pts

• Tumor nephrectomy (TN) specimens– 40% with arteriosclerosis and no TI scarring– 20% with arteriosclerosis and TI scarring

• >20% global glomerulosclerosis predicts progression of CKD

Glomerulosclerosis

Underestimating global glomerulosclerosis

Bijol V, et al. Am J Surg Pathol, 2006; 30: 575-584..

Significance of Global Glomerulosclerosis

• Bijol V, et al:

– Presence of >20% global glomerulosclerosis

or nodular diabetic glomerulosclerosis

predicted an increase of 0.5 mg/dL in serum

creatinine 6 months after surgery

J Urol 2010, 184: 1872-1876.

– Extent of global glomerulosclerosis correlates with the rate of renal function decline in radical nephrectomy specimens

Interstitial fibrosis / tubular atrophy

Arteriosclerosis

Focal Segmental Glomerulosclerosis

• 2 to 9% of TN specimens– Often associated with hypertension,

arteriosclerosis, and parenchyma scarring– May be secondary to reduction of functional

nephrons

• Proteinuria, nephrotic-range (>3 g/day)

• IF: negative

• EM: podocyte foot process effacement

Focal Segmental Glomerulosclerosis

Crescentic GN

Etiologies

1. Pauci-immune (ANCA-associated) GN

2. Anti-glomerular basement membrane (anti-GBM) GN

3. Immune complex-mediated GN • IgA nephropathy• Lupus nephritis• Membranoproliferative GN• Post-infectious GN• Etc.

Pauci-immune crescentic GN

• Uncommon in the setting of kidney cancer

• 80% with positive ANCA titer

• Clinicopathologic entities– Churg-Strauss syndrome– Granulomatosis with

polyangiitis (Wegener)– Microscopic polyangiitis

Crescentic GN

Pitfall – JGA hyperplasia

Pitfall – Collapsing Glomerulopathy

Pauci-immune crescentic GN

Actual Parameter

Non-Neoplastic Kidney (evaluate using PAS and/or Jones methenamine silver stain; check all that apply)____ Insufficient tissue (partial nephrectomy specimen with <5 mm of adjacent non-

neoplastic kidney ____ Sufficient tissue

__ No significant pathologic alterations of the glomeruli, tubules, interstitium, or vessels__ Significant pathologic alterations

Glomeruli (fill all that apply)____ % of glomeruli with global sclerosis (0-100%)____ Glomerular disease (specify): ____________________ Other

Tubulointerstitial compartment (check all that apply)____ No significant abnormalities____ Interstitial fibrosis/tubular atrophy, mild (5-25%) ____ IF/TA, moderate (26-50%)____ IF/TA, severe (>50%)____ Other tubulointerstitial diseases (specify): ______________

Vessels (check all that apply)____ No significant abnormalities____ Arteriosclerosis (mild; <25% occlusion)____ Arteriosclerosis (moderate; 26-50% occlusion)____ Arteriosclerosis (severe; >50% occlusion) ____ Other vascular injuries (specify): ___________________

Proposed Parameter

Future Directions

• Improve coordinated care between urologists

and nephrologists

• Refine therapeutic implications of pathologic

parameters of the non-neoplastic kidney

– % Global glomerulosclerosis

– Severity of interstitial fibrosis / tubular atrophy

– Severity of arteriosclerosis or arteriolosclerosis

Summary

• Chronic Kidney Disease / End-stage renal disease is important

• Non-neoplastic renal diseases are common– Diabetic nephropathy– Arterionephrosclerosis

• Examine the non-neoplastic kidney carefully, especially with benign tumors!

• Order PAS/Jones silver stains

Questions?